Neurotoxic Mechanisms in Parkinson's Disease Models

Parkinson’s disease is characterised by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and consequent depletion of striatal dopamine. Experimental models—most notably the 6-hydroxydopamine lesion, MPTP toxicity and genetic manipulations—have revealed convergent pathways of neuronal injury. Mitochondrial complex I dysfunction generates reactive oxygen species, while disrupted calcium homeostasis and glutamatergic overstimulation via NMDA receptors drive excitotoxic death. Concurrently, activated microglia and astrocytes release pro-inflammatory cytokines and nitric oxide, exacerbating neuronal damage. Misfolding and aggregation of α-synuclein further impair proteostasis, leading to endoplasmic reticulum stress and apoptosis. Signalling through the receptor for advanced glycation end products (RAGE) has emerged as a key amplifier of inflammatory cascades. Moreover, spatiotemporal mapping of degeneration has identified extra-nigrostriatal regions vulnerable to early toxin-induced injury, underscoring the complexity of non-motor manifestations. Collectively, these insights form a mechanistic framework for the rational design of neuroprotective strategies and the validation of novel therapies in preclinical Parkinson’s disease models.

Research from Nature Portfolio

Selective pharmacological inhibition of RAGE in the substantia nigra of toxin-challenged rodents has been shown to block NF-κB activation, limit microglial and astroglial reactivity and preserve tyrosine hydroxylase–positive neurons, resulting in amelioration of motor deficits. In tandem, a novel translational approach to gait analysis has established velocity-dependent regression models that align spatial and temporal locomotor parameters in mice with those observed in people with Parkinson’s. This method offers a quantitative bridge between animal models and clinical movement signatures, enabling cross-species evaluation of neurotoxic impact and therapeutic efficacy.

Neurotoxic Mechanisms in Parkinson's Disease Models publication trend

The graph below shows the total number of articles in neurotoxic mechanisms in parkinson's disease models across all publications each year (not limited to Nature Index journals).

Technical terms

6-Hydroxydopamine (6-OHDA): A neurotoxin that selectively enters dopaminergic neurons to induce lesions mimicking Parkinson’s pathology.

Nigrostriatal pathway: The dopaminergic projection from the substantia nigra to the striatum, critical for voluntary movement control.

Microglia: Resident immune cells of the central nervous system that mediate neuroinflammatory responses to injury.

NMDA receptor: A glutamate-gated ion channel permitting calcium influx, central to excitotoxic neuronal death.

RAGE: Receptor for advanced glycation end products that amplifies inflammatory signalling and contributes to neurodegeneration.

CRISPR/SAM: A gene activation technique using a deactivated Cas9 fused to transcriptional activators to upregulate endogenous genes.

References

1. Mapping of catecholaminergic denervation, neurodegeneration, and inflammation in 6-OHDA-treated Parkinson’s disease mice. npj Parkinson's Disease (2025).
2. Intermittent Theta Burst Stimulation Improves Motor and Behavioral Dysfunction through Modulation of NMDA Receptor Subunit Composition in Experimental Model of Parkinson’s Disease. Cells (2023).
3. CRISPR/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson´s disease. Gene Therapy (2023).
4. Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA–induced dopaminergic denervation. Scientific Reports (2017).
5. A translational approach to capture gait signatures of neurological disorders in mice and humans. Scientific Reports (2017).